Generate Biomedicines, Inc. (NASDAQ: GENB) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Generate Biomedicines, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.84, Generate Biomedicines, Inc. trades at 45.5x sales and 3.3x book value. Over the last twelve months it generated about $28M of revenue and a net loss of $306M. It runs a gross margin of 88.3%, an operating margin of -1030.5% and a net margin of -963.8%. It shows return on equity of -146.1%, return on invested capital of -63.0% and a free cash flow yield of -19.7%. On the balance sheet: a debt-to-equity ratio of 0.20 and a current ratio of 5.01. Over the past 52 weeks the share price ranged from $9.73 to $22.67, with a beta of -0.14.
Generate Biomedicines, Inc. does not currently pay a dividend.
2 Wall Street analyst ratings cover the stock: 2 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Generate Biomedicines, Inc. (GENB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 21.5% / 30% · Interest income / Revenue 98.3% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 21.5% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 98.3% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 21.5% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 98.3% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 4.07% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 78.7% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 98.3% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 78.4% / 33.33% · (Cash+Recv) / Total Assets 78.4% / 33.33% · Interest income / Revenue 98.3% / 5% | Fail |
No. As of September 2026, Generate Biomedicines, Inc. (GENB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Generate Biomedicines, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 98.3% of each dividend: Generate Biomedicines, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.